Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allarity Therapeutics, Inc. - Common stock (NQ: ALLR )

1.280 +0.010 (+0.79%)
Streaming Delayed Price Updated: 2:51 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allarity Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
ALLR CLASS ACTION REMINDER - Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Allarity Therapeutics, Inc. Securities Class Action
From Robbins LLP
Via GlobeNewswire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)
From Glancy Prongay & Murray LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sage, Outset Medical, Allarity, and Super Micro and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Looking Into Allarity Therapeutics's Recent Short Interest
Via Benzinga
ALLR Lawsuit Reminder - Robbins LLP Reminds Stockholders of the Allarity Therapeutics, Inc. Class Action Lawsuit
From Robbins LLP
Via Business Wire
ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Allarity Therapeutics, Inc. (ALLR) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ALLARITY ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Allarity Therapeutics, Inc. (ALLR) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Allarity Therapeutics, Inc.
From Robbins LLP
Via GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Allarity Therapeutics, Inc. (ALLR) Investors
From Law Offices of Howard G. Smith
Via Business Wire
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)
From Allarity Therapeutics, Inc.
Via GlobeNewswire
ALLARITY THERAPEUTICS, INC. ANNOUNCEMENT: If You Have Suffered Losses in Allarity Therapeutics, Inc. (NASDAQ: ALLR), You Are to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
ALLR Stock Earnings: Allarity Therapeutics Beats EPS for Q2 2024
ALLR stock results show that Allarity Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Continues Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
From Allarity Therapeutics, Inc.
Via GlobeNewswire
ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Rosen Law Firm Encourages Allarity Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALLR
From Rosen Law Firm
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.